SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000886163-23-000024
Filing Date
2023-05-04
Accepted
2023-05-04 16:06:01
Documents
14
Period of Report
2023-05-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lgnd-20230504.htm   iXBRL 8-K 33703
2 EX-99.1 q12023earningsrelease_ex991.htm EX-99.1 162719
6 LIGAND LOGO image1a.jpg GRAPHIC 36525
  Complete submission text file 0000886163-23-000024.txt   402547

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lgnd-20230504.xsd EX-101.SCH 1909
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lgnd-20230504_lab.xml EX-101.LAB 24132
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lgnd-20230504_pre.xml EX-101.PRE 12516
8 EXTRACTED XBRL INSTANCE DOCUMENT lgnd-20230504_htm.xml XML 10864
Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

IRS No.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33093 | Film No.: 23888628
SIC: 2834 Pharmaceutical Preparations